Zu Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zu Ye has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Yin Shi
Department of Biochemistry and Department of Pulmonology, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
20 shared publications - Ji Jing
Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
17 shared publications - John A. Tainer
10Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
15 shared publications - Yangchan Hu
Zhejiang Cancer Hospital 2 , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
12 shared publications - Yixing Huang
Otolaryngology and Head and Neck Center, Cancer Center, Department of Otolaryngology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, China
12 shared publications - Chenlong You
Zhejiang Cancer Hospital 2 , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
11 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Elsevier in SSRN Electronic Journal
USP48 Sustains Mitochondrial Homeostasis to Suppress Anti-tumor Immunity by Deubiquitinating LRPPRC in Colorectal Cancer
Mitochondrial redox and metabolic homeostasis are essential for cellular adaptation to stress, yet how disruption of this balance creates selective therapeutic vulnerabilities and shapes tumor immunogenicity remains poorly understood. Here, we identify USP48 as a regulator of mitochondrial homeostasis that determines the susceptibility of colorectal cancer (CRC) cells to ouabain (OUA). Clinically, USP48 is frequently downregulated or genetically inactivated in CRC, and reduced USP48 expression is associated with poor survival. High-throughput screening revealed that USP48 deficiency selectively sensitizes CRC cells to OUA-induced GSDMC-dependent pyroptosis. Mechanistically, USP48 deubiquitinates and stabilizes LRPPRC, a core mitochondrial regulator, thereby sustaining mitochondrial redox and metabolic homeostasis. In USP48-deficient cells, OUA induces extensive mitochondrial DNA (mtDNA) release accompanied by GSDMC-dependent pyroptosis. The released mtDNA activates dendritic cells and engages the host cGAS-STING-IFNAR1 signaling axis to elicit robust anti-tumor immunity, whereas genetic ablation of GSDMC or host STING/IFNAR1 abolishes these effects.Collectively, our findings reveal a previously unrecognized USP48–LRPPRC regulatory link between ubiquitination-mediated mitochondrial quality control and redox homeostasis, and identify USP48 deficiency as a therapeutically exploitable vulnerability that couples mitochondrial stress and mtDNA release to tumor immunogenicity in CRC.
- 22 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessUSP48 Sustains Mitochondrial Homeostasis to Suppress Anti-tumor Immunity by Deubiquitinating LRPPRC in Colorectal Cancer
Mitochondrial redox and metabolic homeostasis are essential for cellular adaptation to stress, yet how disruption of this balance creates selective therapeutic vulnerabilities and shapes tumor immunogenicity remains poorly understood. Here, we identify USP48 as a regulator of mitochondrial homeostasis that determines the susceptibility of colorectal cancer (CRC) cells to ouabain (OUA). Clinically, USP48 is frequently downregulated or genetically inactivated in CRC, and reduced USP48 expression is associated with poor survival. High-throughput screening revealed that USP48 deficiency selectively sensitizes CRC cells to OUA-induced GSDMC-dependent pyroptosis. Mechanistically, USP48 deubiquitinates and stabilizes LRPPRC, a core mitochondrial regulator, thereby sustaining mitochondrial redox and metabolic homeostasis. In USP48-deficient cells, OUA induces extensive mitochondrial DNA (mtDNA) release accompanied by GSDMC-dependent pyroptosis. The released mtDNA activates dendritic cells and engages the host cGAS-STING-IFNAR1 signaling axis to elicit robust anti-tumor immunity, whereas genetic ablation of GSDMC or host STING/IFNAR1 abolishes these effects.Collectively, our findings reveal a previously unrecognized USP48–LRPPRC regulatory link between ubiquitination-mediated mitochondrial quality control and redox homeostasis, and identify USP48 deficiency as a therapeutically exploitable vulnerability that couples mitochondrial stress and mtDNA release to tumor immunogenicity in CRC.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S2 demonstrates that PARG inhibition synergizes with fluoropyrimidines.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S2 demonstrates that PARG inhibition synergizes with fluoropyrimidines.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S1 shows PARG upregulation, independent prognostic value, and PARG inhibitor characterization in GC.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S1 shows PARG upregulation, independent prognostic value, and PARG inhibitor characterization in GC.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S3 confirms that combining PARG inhibitor with 5-FU does not cause significant body weight loss or major organ toxicity in PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S3 confirms that combining PARG inhibitor with 5-FU does not cause significant body weight loss or major organ toxicity in PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S4 shows that capecitabine plus PARG inhibitor treatment is well tolerated in PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S4 shows that capecitabine plus PARG inhibitor treatment is well tolerated in PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S5 shows that PARG deficiency or inhibition exacerbates 5-FU-induced DNA damage.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S5 shows that PARG deficiency or inhibition exacerbates 5-FU-induced DNA damage.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S6 demonstrates that PARG deficiency reduces RAD51AP1 localization to DNA damage sites and promotes 5-FU-induced genomic instability.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S6 demonstrates that PARG deficiency reduces RAD51AP1 localization to DNA damage sites and promotes 5-FU-induced genomic instability.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S7 provides biochemical evidence of direct PARG–RAD51AP1 interaction and PAR-dependent ubiquitination.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S7 provides biochemical evidence of direct PARG–RAD51AP1 interaction and PAR-dependent ubiquitination.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S9 confirms RAD51AP1 upregulation and positive correlation with PARG in GC tissues.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S9 confirms RAD51AP1 upregulation and positive correlation with PARG in GC tissues.